{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:25:42Z","timestamp":1791584742644,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Doctoral Scientific Research Start-up Foundation of Luohe Medical College","award":["(No. 2022-DF-02"],"award-info":[{"award-number":["(No. 2022-DF-02"]}]},{"name":"Key Research Projects of Higher Education Institutions in Henan Province","award":["No. 24B310002"],"award-info":[{"award-number":["No. 24B310002"]}]},{"name":"Luohe Medical College Science and Technology Innovation Project","award":["No. 2023ZD01"],"award-info":[{"award-number":["No. 2023ZD01"]}]},{"name":"Science and Technology Research Project of Henan Provincial Department of Science and Technology","award":["No. 232102310216"],"award-info":[{"award-number":["No. 232102310216"]}]},{"name":"Science and Technology Research Project of Henan Provincial Department of Science and Technology","award":["252102310393"],"award-info":[{"award-number":["252102310393"]}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["No. 252300420627"],"award-info":[{"award-number":["No. 252300420627"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02934-0","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:33:34Z","timestamp":1749724414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comprehensive analysis of SELPLG as a potential immunotherapy target and prognostic biomarker in oncology"],"prefix":"10.1007","volume":"16","author":[{"given":"Ranran","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoju","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2934_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","volume":"10","author":"N Budimir","year":"2022","unstructured":"Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing t-cell exhaustion in cancer: lessons learned from pd-1\/pd-l1 immune checkpoint Blockade. Cancer Immunol Res. 2022;10:146\u201353.","journal-title":"Cancer Immunol Res"},{"key":"2934_CR2","doi-asserted-by":"publisher","first-page":"636238","DOI":"10.3389\/fimmu.2021.636238","volume":"12","author":"JM DeRogatis","year":"2021","unstructured":"DeRogatis JM, Viramontes KM, Neubert EN, Tinoco R. Psgl-1 immune checkpoint Inhibition for cd4(+) t cell cancer immunotherapy. Front Immunol. 2021;12:636238.","journal-title":"Front Immunol"},{"key":"2934_CR3","doi-asserted-by":"publisher","first-page":"e92327","DOI":"10.1371\/journal.pone.0092327","volume":"9","author":"F Heidemann","year":"2014","unstructured":"Heidemann F, Schildt A, Schmid K, Bruns OT, Riecken K, Jung C, et al. Selectins mediate small cell lung cancer systemic metastasis. PLoS ONE. 2014;9:e92327.","journal-title":"PLoS ONE"},{"key":"2934_CR4","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119:1468\u201378.","journal-title":"Blood"},{"key":"2934_CR5","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1158\/0008-5472.CAN-04-4653","volume":"65","author":"CJ Dimitroff","year":"2005","unstructured":"Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, et al. Identification of leukocyte e-selectin ligands, p-selectin glycoprotein ligand-1 and e-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res. 2005;65:5750\u201360.","journal-title":"Cancer Res"},{"key":"2934_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s12253-012-9531-y","volume":"18","author":"L Gong","year":"2012","unstructured":"Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells through p-selectin glycoprotein ligand-1. Pathol Oncol Res. 2012;18:989\u201396.","journal-title":"Pathol Oncol Res"},{"key":"2934_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1586\/14737140.8.8.1247","volume":"8","author":"L Borsig","year":"2008","unstructured":"Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8:1247\u201355.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2934_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/leu.2012.272","volume":"27","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, et al. Psgl-1\/selectin and icam-1\/cd18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013;27:702\u201310.","journal-title":"Leukemia"},{"key":"2934_CR9","doi-asserted-by":"publisher","first-page":"417586","DOI":"10.1155\/2015\/417586","volume":"2015","author":"B Muz","year":"2015","unstructured":"Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, et al. Inhibition of p-selectin and psgl-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib. Biomed Res Int. 2015;2015:417586.","journal-title":"Biomed Res Int"},{"key":"2934_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3389\/fcell.2020.00668","volume":"8","author":"J Erbani","year":"2020","unstructured":"Erbani J, Tay J, Barbier V, Levesque JP, Winkler IG. Acute myeloid leukemia chemo-resistance is mediated by e-selectin receptor cd162 in bone marrow niches. Front Cell Dev Biol. 2020;8:668.","journal-title":"Front Cell Dev Biol"},{"key":"2934_CR11","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1002\/art.38808","volume":"66","author":"A Perez-Frias","year":"2014","unstructured":"Perez-Frias A, Gonzalez-Tajuelo R, Nunez-Andrade N, Tejedor R, Garcia-Blanco MJ, Vicente-Rabaneda E, et al. Development of an autoimmune syndrome affecting the skin and internal organs in p-selectin glycoprotein ligand 1 leukocyte receptor-deficient mice. Arthritis Rheumatol. 2014;66:3178\u201389.","journal-title":"Arthritis Rheumatol"},{"key":"2934_CR12","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.4049\/jimmunol.1301235","volume":"191","author":"S Angiari","year":"2013","unstructured":"Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, et al. Regulatory t cells suppress the late phase of the immune response in lymph nodes through p-selectin glycoprotein ligand-1. J Immunol. 2013;191:5489\u2013500.","journal-title":"J Immunol"},{"key":"2934_CR13","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.4049\/jimmunol.177.12.8748","volume":"177","author":"X He","year":"2006","unstructured":"He X, Schoeb TR, Panoskaltsis-Mortari A, Zinn KR, Kesterson RA, Zhang J, et al. Deficiency of p-selectin or p-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of Cc chemokine ligand 2 in lupus-prone mice. J Immunol. 2006;177:8748\u201356.","journal-title":"J Immunol"},{"key":"2934_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/path.2850","volume":"224","author":"N Nunez-Andrade","year":"2011","unstructured":"Nunez-Andrade N, Lamana A, Sancho D, Gisbert JP, Gonzalez-Amaro R, Sanchez-Madrid F, et al. P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria. J Pathol. 2011;224:212\u201321.","journal-title":"J Pathol"},{"key":"2934_CR15","doi-asserted-by":"crossref","unstructured":"Tinoco R, Carrette F, Barraza ML, Otero DC, Maga\u00f1a J, Bosenberg MW et al. Psgl-1 is an immune checkpoint regulator that promotes t cell exhaustion. Immunity. 2016;44:1190\u2009\u2013\u2009203.","DOI":"10.1016\/j.immuni.2016.04.015"},{"key":"2934_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1158\/2326-6066.CIR-21-0690","volume":"10","author":"JM DeRogatis","year":"2022","unstructured":"DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R. Targeting the psgl-1 immune checkpoint promotes immunity to pd-1-resistant melanoma. Cancer Immunol Res. 2022;10:612\u201325.","journal-title":"Cancer Immunol Res"},{"key":"2934_CR17","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.4049\/jimmunol.179.11.7457","volume":"179","author":"A Urzainqui","year":"2007","unstructured":"Urzainqui A, Martinez del Hoyo G, Lamana A, de la Fuente H, Barreiro O, Olazabal IM, et al. Functional role of p-selectin glycoprotein ligand 1\/p-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol. 2007;179:7457\u201365.","journal-title":"J Immunol"},{"key":"2934_CR18","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.1074\/jbc.M111.318022","volume":"287","author":"C Spertini","year":"2012","unstructured":"Spertini C, Baisse B, Spertini O. Ezrin-radixin-moesin-binding sequence of psgl-1 glycoprotein regulates leukocyte rolling on selectins and activation of extracellular signal-regulated kinases. J Biol Chem. 2012;287:10693\u2013702.","journal-title":"J Biol Chem"},{"key":"2934_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1074-7613(02)00420-X","volume":"17","author":"A Urzainqui","year":"2002","unstructured":"Urzainqui A, Serrador JM, Viedma F, Yanez-Mo M, Rodriguez A, Corbi AL, et al. Itam-based interaction of erm proteins with Syk mediates signaling by the leukocyte adhesion receptor psgl-1. Immunity. 2002;17:401\u201312.","journal-title":"Immunity"},{"key":"2934_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12935-020-01472-9","volume":"20","author":"F Bi","year":"2020","unstructured":"Bi F, Chen Y, Yang Q. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int. 2020;20:373.","journal-title":"Cancer Cell Int"},{"key":"2934_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"2934_CR22","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD et al. An integrated tcga pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400\u2009\u2013\u200916 e11."},{"key":"2934_CR23","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH et al. The immune landscape of cancer. Immunity. 2018;48:812\u2009\u2013\u200930 e14."},{"key":"2934_CR24","doi-asserted-by":"crossref","unstructured":"Liu Z, Liu L, Weng S, Xu H, Xing Z, Ren Y et al. Best: A web application for comprehensive biomarker exploration on large-scale data in solid tumors. Journal of Big Data. 2023;10:165.","DOI":"10.1186\/s40537-023-00844-y"},{"key":"2934_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/0008-5472.CAN-23-1307","volume":"84","author":"Y Xu","year":"2024","unstructured":"Xu Y, Deng C, Chen H, Song Y, Xu H, Song G, et al. Osteosarcoma cells secrete cxcl14 that activates integrin \u03b111\u03b21 on fibroblasts to form a lung metastatic niche. Cancer Res. 2024;84:994\u20131012.","journal-title":"Cancer Res"},{"key":"2934_CR26","doi-asserted-by":"publisher","first-page":"e2410427","DOI":"10.1002\/advs.202410427","volume":"12","author":"T Luo","year":"2025","unstructured":"Luo T, Fan Z, Zeng A, Wang A, Pan Y, Xu Y, et al. Biomimetic targeted co-delivery system engineered from genomic insights for precision treatment of osteosarcoma. Adv Sci (Weinh). 2025;12:e2410427.","journal-title":"Adv Sci (Weinh)"},{"key":"2934_CR27","doi-asserted-by":"crossref","unstructured":"Petty AJ, Owen DH, Yang Y, Huang X. Targeting tumor-associated macrophages in cancer immunotherapy. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13215318"},{"key":"2934_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-021-00252-z","volume":"10","author":"S Zhu","year":"2021","unstructured":"Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2021;10:60.","journal-title":"Exp Hematol Oncol"},{"key":"2934_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","volume":"42","author":"A Sica","year":"2006","unstructured":"Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct m2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717\u201327.","journal-title":"Eur J Cancer"},{"key":"2934_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"2934_CR31","doi-asserted-by":"publisher","first-page":"e0153550","DOI":"10.1371\/journal.pone.0153550","volume":"11","author":"M Zhang","year":"2016","unstructured":"Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, et al. Anti-cd47 treatment stimulates phagocytosis of glioblastoma by m1 and m2 polarized macrophages and promotes m1 polarized macrophages in vivo. PLoS ONE. 2016;11:e0153550.","journal-title":"PLoS ONE"},{"key":"2934_CR32","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1158\/2767-9764.CRC-22-0513","volume":"3","author":"K Kauffman","year":"2023","unstructured":"Kauffman K, Manfra D, Nowakowska D, Zafari M, Nguyen PA, Phennicie R, et al. Psgl-1 Blockade induces classical activation of human tumor-associated macrophages. Cancer Res Commun. 2023;3:2182\u201394.","journal-title":"Cancer Res Commun"},{"key":"2934_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.it.2017.02.002","volume":"38","author":"R Tinoco","year":"2017","unstructured":"Tinoco R, Otero DC, Takahashi AA, Bradley LM. Psgl-1: A new player in the immune checkpoint landscape. Trends Immunol. 2017;38:323\u201335.","journal-title":"Trends Immunol"},{"key":"2934_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. Vista is an acidic ph-selective ligand for psgl-1. Nature. 2019;574:565\u201370.","journal-title":"Nature"},{"key":"2934_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00262-024-03701-w","volume":"73","author":"M Olbromski","year":"2024","unstructured":"Olbromski M, Mrozowska M, Piotrowska A, Smolarz B, Romanowicz H. The vista\/vsig3\/psgl-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma. Cancer Immunol Immunother. 2024;73:136.","journal-title":"Cancer Immunol Immunother"},{"key":"2934_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1074\/jbc.M204360200","volume":"278","author":"MP Bernimoulin","year":"2003","unstructured":"Bernimoulin MP, Zeng XL, Abbal C, Giraud S, Martinez M, Michielin O, et al. Molecular basis of leukocyte rolling on psgl-1. Predominant role of core-2 o-glycans and of tyrosine sulfate residue 51. J Biol Chem. 2003;278:37\u201347.","journal-title":"J Biol Chem"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02934-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:33:37Z","timestamp":1749724417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02934-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2934"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02934-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they agree to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1073"}}